Results 131 to 140 of about 15,373 (177)

Capivasertib as a Therapeutic Agent for Breast Cancer: Targeting AKT to Overcome Endocrine Resistance. [PDF]

J Clin Med
Damaskos C, Garmpis N, Arkadopoulos N, Michalopoulos NV, Garmpi A, Papandroudis MP, Effraimidou EI.   +6 more
europepmc   +1 more source

Capivasertib for locally advanced or metastatic breast cancer. [PDF]

Aust Prescr
europepmc   +1 more source

Assessing the utility of ctDNA as a prognostic marker in advanced ER-positive/HER2-negative breast cancer. [PDF]

Transl Cancer Res
Chaki M, Morrow C, Ahlgren H.
europepmc   +1 more source

Review of ctDNA in breast cancer - present utility and future perspectives. [PDF]

Rep Pract Oncol Radiother
Suryavanshi M, Razdan S, Kumar M.
europepmc   +1 more source

Targeting Semaphorin 7a signaling in preclinical models of endocrine therapy-resistant breast cancer. [PDF]

Mol Cancer Ther
Steinmetz RN, Wessells V, Fairchild H, Borges VF, Lyons TR.   +4 more
europepmc   +1 more source

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer. [PDF]

ESMO Open
Im SA, Kalinsky K, Jhaveri KL, Loibl S, Turner N, Saura C, Schmid P, Loi S, Hamilton E, Karadurmus N, Wang S, Awan AA, Ciruelos EM, Chung CF, Thanopoulou E, Shankar N, Lim S, Jin Y, Song C, Juric D.   +19 more
europepmc   +1 more source

Time-varying hazard rates reveal patterns of progression in HR+/HER2- metastatic breast cancer: Towards risk-adapted monitoring. [PDF]

Transl Oncol
Cucciniello L, Giudici F, Foffano L, Franzoni A, Pastò B, Molteni E, Della Rossa S, Pascoletti G, Spazzapan S, Musco L, Di Giustino G, Da Ros L, Vida R, Poletto E, Nascimbeni E, Bonotto M, Marco Minisini A, Belletti B, Damante G, Gerratana L, Puglisi F.   +20 more
europepmc   +1 more source

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia. [PDF]

Int J Mol Sci
Quagliariello V, Berretta M, Barbato M, Maurea F, Canale ML, Paccone A, Bisceglia I, Tedeschi A, Scherillo M, Santagata J, Oliva S, Dessalvi CC, Forte P, D'Ambrosio C, Matola TD, Parmentola R, Gabrielli D, Maurea N.   +17 more
europepmc   +1 more source

Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer. [PDF]

Curr Treat Options Oncol
Cetin B, Erdem D, Karaman I, Gumusay O.
europepmc   +1 more source